Study of Magrolimab Given Together With FOLFIRI/BEV in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Sponsor
Gilead Sciences (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05330429
Collaborator
(none)
215
2
3
51.8
107.5
2.1

Study Details

Study Description

Brief Summary

The primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
215 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Actual Study Start Date :
Jul 8, 2022
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
Nov 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Safety Run-in Cohort: Magrolimab + Bevacizumab + FOLFIRI

Participants will receive magrolimab in de-escalating doses to establish recommended Phase 2 dose (RP2D) in combination with + bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 + leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).

Drug: Magrolimab
Administered intravenously
Other Names:
  • GS-4721
  • Drug: Bevacizumab
    Administered intravenously

    Drug: Irinotecan
    Administered intravenously
    Other Names:
  • CAMPTOSAR┬«
  • Drug: Fluorouracil
    Administered intravenously

    Drug: Leucovorin
    Administered intravenously

    Experimental: Randomized Cohort: Magrolimab + Bevacizumab + FOLFIRI

    Participants will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 + leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle). Additional dose expansion cohorts of magrolimab in combination with bevacizumab and FOLFIRI may be opened at the sponsor's discretion.

    Drug: Magrolimab
    Administered intravenously
    Other Names:
  • GS-4721
  • Drug: Bevacizumab
    Administered intravenously

    Drug: Irinotecan
    Administered intravenously
    Other Names:
  • CAMPTOSAR┬«
  • Drug: Fluorouracil
    Administered intravenously

    Drug: Leucovorin
    Administered intravenously

    Active Comparator: Randomized Cohort: Bevacizumab + FOLFIRI

    Participants will receive bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 +leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).

    Drug: Bevacizumab
    Administered intravenously

    Drug: Irinotecan
    Administered intravenously
    Other Names:
  • CAMPTOSAR┬«
  • Drug: Fluorouracil
    Administered intravenously

    Drug: Leucovorin
    Administered intravenously

    Outcome Measures

    Primary Outcome Measures

    1. Safety Run-in Cohort: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [First dose date up to 28 days]

    2. Safety Run-in Cohort: Percentage of Participants Experiencing Adverse Events (AEs) According to the NCI-CTCAE Version 5.0 [First dose date up to 3 years]

    3. Safety Run-in Cohort: Percentage of Participants Experiencing Laboratory Abnormalities According to NCI-CTCAE Version 5.0 [First dose date up to 3 years]

    4. Randomized Cohort: Progression-free Survival (PFS) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 [Up to 3 years]

      PFS is defined as the time from the date of randomization until the earliest date of documented disease progression, or death from any cause, whichever occurs first.

    Secondary Outcome Measures

    1. Randomized Cohort: Objective Response Rate (ORR) as Determined by Investigator Assessment Using RECIST Version 1.1 [Up to 3 years]

      Confirmed ORR is defined as the proportion of participants with complete response (CR) or partial response (PR) on 2 consecutive assessments, at least 28 days apart.

    2. Randomized Cohort: ORR as Determined by Independent Central Review Using RECIST Version 1.1 [Up to 3 years]

      Confirmed ORR is defined as the proportion of participants with complete response (CR) or partial response (PR) on 2 consecutive assessments, at least 28 days apart.

    3. Randomized Cohort: PFS as Determined by Independent Central Review Per RECIST Version 1.1 [Up to 3 years]

      PFS is defined as the time from the date of randomization until the earliest date of documented disease progression, or death from any cause, whichever occurs first.

    4. Randomized Cohort: Duration of Response (DOR) as Assessed by Investigator Assessment Per RECIST Version 1.1 [Up to 3 years]

      DOR is defined as time from first documentation of CR or PR to the earliest date of documented disease progression, or death from any cause, whichever occurs first.

    5. Randomized Cohort: Duration of Response (DOR) as Assessed by Independent Central Review Per RECIST Version 1.1 [Up to 3 years]

      DOR is defined as time from first documentation of CR or PR to the earliest date of documented disease progression, or death from any cause, whichever occurs first.

    6. Randomized Cohort: Overall Survival (OS) [Up to 3 years]

      OS is defined as time from date of randomization to death from any cause.

    7. Randomized Cohort: Change From Baseline of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire EORTC-QLQ-C30 Score [Baseline, up to 3 years]

      The EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients, it is composed of 30 questions (items) resulting in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single items. Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the participant), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the participant).

    8. Randomized Cohort: Change From Baseline of the 5-level EuroQol 5 dimensions questionnaire (EQ-5D-5L) Score [Baseline, up to 3 years]

      EQ-5D-5L is an instrument for use as a measure of health outcome.The EQ-5D-5L consists of 2 sections: the EuroQoL (5 dimensions) (EQ-5D) descriptive system and the EuroQoL visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ-VAS indicate better health.

    9. Randomized Cohort: the Change From Baseline of the Functional Assessment of Cancer Therapy (FACT) Colorectal Symptom Index (FCSI) Score [Baseline, up to 3 years]

      The FCSI is a set of brief, clinically relevant, colorectal cancer symptoms for assessing symptomatic response. It comprises the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state.

    10. Safety Run-in and Randomized Cohorts: Magrolimab Concentration Versus Time [Up to end of treatment (approximately 3 years)]

    11. Safety Run-in and Randomized Cohorts: Antidrug Antibodies (ADA) to Magrolimab [Up to end of treatment (approximately 3 years)]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Key Inclusion Criteria:
    • Previously treated individuals with inoperable metastatic colorectal cancer (mCRC) who are ineligible for checkpoint inhibitor therapy (microsatellite instability (MSI)-H or mismatch repair deficient (dMMR) and are excluded).

    • Histologically or cytologically confirmed adenocarcinoma originating in the colon or rectum (excluding appendiceal and anal canal cancers), who have progressed on or after 1 prior systemic therapy with chemotherapy based on 5-fluorouracil (5-FU) with oxaliplatin and bevacizumab.

    • Measurable disease (RECIST V1.1 criteria)

    • Individuals must have an eastern cooperative oncology group (ECOG) performance status of 0 or 1.

    • Life expectancy of at least 12 weeks.

    • Laboratory measurements, blood counts: adequate hemoglobin, neutrophil, and platelet counts

    • Adequate liver function

    • Adequate renal function

    Key Exclusion Criteria:
    • Prior anticancer therapy including chemotherapy, hormonal therapy, or investigational agents within 3 weeks or within at least 4 half-lives prior to magrolimab dosing (up to a maximum of 4 weeks), whichever is shorter.

    • Known v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E or MSI-H mutations or dMMR.

    • Persistent Grade 2 or more gastrointestinal bleeding.

    • Individuals with prior irinotecan therapy.

    • Individuals without prior bevacizumab therapy for colorectal cancer.

    • Clinically significant coronary artery disease or myocardial infarction within 6 months prior to inclusion.

    • Peripheral neuropathy of more than Grade 1 (CTCAE Version 5.0).

    • Known dihydropyrimidine dehydrogenase deficiency.

    • Acute intestinal obstruction or subobstruction, history of inflammatory intestinal disease or extended resection of the small intestine. Presence of a colic prosthesis.

    • Unhealed wound, active gastric or duodenal ulcer, or bone fracture.

    • History of abdominal fistulas, trachea-oesophageal fistulas, any other Grade 4 gastrointestinal perforations, nongastrointestinal fistulas, or intra-abdominal abscesses 6 months prior to screening.

    • Uncontrolled arterial hypertension.

    • Thromboembolic event in the 6 months before inclusion (eg, transitory ischemic stroke, stroke, subarachnoid hemorrhage) except peripheral deep vein thrombosis treated with anticoagulants.

    • Active central nervous system (CNS) disease. Individuals with asymptomatic and stable, treated CNS lesions (radiation and/or surgery and/or other CNS-directed therapy who have not received corticosteroids for at least 4 weeks) are allowed.

    • Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of packed RBC transfusions during the 4-week period prior to screening.

    • History of hemolytic anemia, autoimmune thrombocytopenia, or Evans syndrome in the last 3 months.

    • Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient.

    • Known inherited or acquired bleeding disorders.

    • Significant disease or medical conditions, as assessed by the investigator and sponsor, that would substantially increase the risk-benefit ratio of participating in the study.

    • Second malignancy, except treated basal cell or localized squamous skin carcinomas, or localized prostate cancer

    • Known active or chronic hepatitis B or C infection or HIV infection in medical history.

    • Uncontrolled pleural effusion.

    Note: Other protocol defined Inclusion/Exclusion criteria may apply.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 City of Hope ( City of Hope National Medical Center, City of Hope Medical Center ) Duarte California United States 91010
    2 Genesis Care North Shore St Leonards New South Wales Australia 2065

    Sponsors and Collaborators

    • Gilead Sciences

    Investigators

    • Study Director: Gilead Study Director, Gilead Sciences

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Gilead Sciences
    ClinicalTrials.gov Identifier:
    NCT05330429
    Other Study ID Numbers:
    • GS-US-587-6156
    • 2022-500177-13-00
    First Posted:
    Apr 15, 2022
    Last Update Posted:
    Aug 5, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 5, 2022